Atrial fibrillation during or after TAVI: Incidence, implications and therapeutical considerations

Current Pharmaceutical Design

Volumn 22, Issue 13, 2016, Pages 1896-1903

  Vavuranakis, Manolis ^a,b   Kolokathis, Angelos Michail ^a   Vrachatis, Dimitrios A ^a   Kalogeras, Konstantinos ^a   Magkoutis, Nikolaos A ^c   Fradi, Sabi ^c   Ghostine, Saïd ^c   Karamanou, Marianna ^d   Tousoulis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b OHIO STATE UNIVERSITY   (United States)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Antithrombotic therapy; Aortic stenosis; Atrial fibrillation; NOAF; TAVI

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; THIENOPYRIDINE DERIVATIVE;

ANTICOAGULANT THERAPY; AORTA STENOSIS; ARTICLE; CARDIAC MUSCLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); ELECTROCARDIOGRAPHY MONITORING; GLOMERULUS FILTRATION RATE; HEART ATRIUM ENLARGEMENT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE INJURY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; MULTICENTER STUDY (TOPIC); NEW-ONSET ATRIAL FIBRILLATION; PERCUTANEOUS AORTIC VALVE; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGICAL RISK; SYSTEMATIC REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ADVERSE EFFECTS; ATRIAL FIBRILLATION;

ATRIAL FIBRILLATION; HUMANS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84964253380     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151208123050     Document Type: Article

References (72)

1. Lung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on valvular heart disease. Eur Heart J 2003; 24: 1231-43.
2. Vavuranakis M, Voudris V, Vrachatis DA, et al. Transcatheter aortic valve implantation, patient selection process and procedure: two centres’ experience of the intervention without general anaesthesia. Hell J Cardiol 2010; 51(6): 492-500
3. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597-607.
4. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187-98
5. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk. Acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010; 55: 1080-90.
6. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005; 26(24): 2714-20.
7. Eggebrecht H, Schmermund A, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. Euro Intervent 2012; 8(1): 129-38
8. Fuster, Valentin. "ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society". Circulation 2006; 114(7): e257-354.
9. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004; 110(9): 1042-6
10. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113(5): 359-364
11. Schulenberg R, Antonitsis P, Stroebel A, Westaby S. Chronic atrial fibrillation is associated with reduced survival after aortic and double valve replacement. Ann Thorac Surg 2010; 89: 738-44.
12. Saxena A, Shi WY, Bappayya S, et al. Postoperative atrial fibrillation after isolated aortic valve replacement: a cause for concern? Ann Thorac Surg 2013; 95(1): 133-40.
13. Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation 2009; 119(23): 3009-16.
14. Buellesfeld L, Gerckens U, Schuler G, et al. 2-year follow-up of patients undergoing transcatheter aortic valve implantation using a self-expanding valve prosthesis. J Am Coll Cardiol 2011; 57(16): 1650-7.
15. Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010; 121(7): 870-8.
16. Ghanem A, Muller A, Nahle CP, et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol 2010; 55(14): 1427-32.
17. Miller DC, Blackstone EH, Mack MJ, et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the Partner trial. J Thorac Cardiovasc Surg 2012; 143: 832-43.
18. Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg 2012; 42(5): S45-60
19. Roten L, Stortecky S, Scarcia F, et al. Atrioventricular conduction af-ter transcatheter aortic valve implantation and surgical aortic valve replacement. J Cardiovasc Electrophysiol 2012; 23(10): 1115-22
20. Appel CF, Hultkvist H, Nylander E, et al. Transcatheter versus surgical treatment for aortic stenosis: patient selection and early outcome. Scand Cardiovasc J 2012; 46(5): 301-7.
21. Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implanta-tion. Circulation 2012; 126(25): 3041-53.
22. Motloch LJ, Reda S, Rottlaender D, et al. Postprocedural atrial fibril-lation after transcatheter aortic valve implantation versus surgical aortic valve replacement. Ann Thorac Surg 2012; 93(1): 124-31.
23. Amat-Santos IJ, Rodes-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 59(2): 178-88.
24. Rodes-Cabau J, Gutierrez M, Bagur R, et al. Incidence, predictive factors, and prognostic value of myocardial injury following uncomplicated transcatheter aortic valve implantation. J Am Coll Cardiol 2011; 57(20): 1988-99
25. Nuis RJ, Van Mieghem NM, Schultz CJ, et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol 2012; 109(11): 1637-43.
26. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aorticvalve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370(19): 1790-8.
27. Salinas P, Moreno R, Calvo L, et al. Clinical and prognostic implications of atrial fibrillation in patients undergoing transcatheter aortic valve implantation. World J Cardiol 2012; 4(1): 8-14.
28. Stortecky S, Buellesfeld L, Wenaweser P, et al. Atrial fibrillation and aortic stenosis: impact on clinical outcomes among patients under-going transcatheter aortic valve implantation. Circ Cardiovasc In-terv 2013; 6(1): 77-84.
29. Yankelson L, Steinvil A, Gershovitz L, et al. Atrial fibrillation, stroke, and mortality rates after transcatheter aortic valve implantation. Am J Cardiol 2014; 114(12): 1861-6
30. Linke A, Gerckens U, Wenaweser P, et al. Treatment of high risk aortic stenosis patients with transcatheter Medtronic CoreValve implantation: results from the international multicenter advance study. J Am Coll Cardiol 2012; 59: e8
31. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for Surgery, Popma JJ, Adams DH, et al. CoreValve United States Clinical Investigators. J Am Coll Cardiol 2014; 63(19): 1972-81.
32. Lenders GD, Paelinck BP, Wouters K, et al. Transesophageal echocardiography for cardiac thromboembolic risk assessment in patients with severe, symptomatic aortic valve stenosis referred for potential transcatheter aortic valve implantation. Am J Cardiol 2013; 111(10): 1470-4.
33. Rodés-Cabau J, Webb JG, Cheung A, et al. Long-term outcomes after transca-theter aortic valve implantation: insights on prognostic factors and valve dura-bility from the Canadian multicenter experience. J Am Coll Cardiol 2012; 60: 1864-75.
34. Clavel MA, Rodés-Cabau J, Masson JB, et al. Comparison between transcatheter and surgical prosthetic valve implantation in patients with severe aortic stenosis and reduced left ventricular ejection fraction. Circulation 2010; 122(19): 1928-36.
35. Josep Rodés-Cabau, Harold L. Dauerman, Mauricio G. Cohen, et al. Antithrombotic treatment in transcatheter aortic valve implantationinsights for cerebrovascular and bleeding events. J Am Coll Cardiol 2013; 62(25): 2349-59.
36. Nijenhuis VJ, Bennaghmouch N, van Kuijk JP, Capodanno D, Ten Berg JM1. Antithrombotic treatment in patients undergoing transcatheter aortic valve implantation (TAVI). Thromb Haemost 2015; 113(4): 674-85.
37. Poliacikova P, Cockburn J, de Belder A, Trivedi U, HildickSmith D. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation—comparison of regimes. J Invasive Cardiol 2013; 25(10): 544-8
38. Collet JP, Montalescot G. Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field? Euro Intervent 2013; 9: S43-7.
39. Lynch DR Jr, Dantzler D, Robbins M, Zhao D. Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation. J Thromb Thromb 2013; 35(4): 476-82.
40. Zeymer U, Zahn R, Gerckens U, Richardt G, Figulla HR, SengesJ. Antithrombotic therapy after transfemoral aortic valve implantation (TAVI). Potential hazard of triple-therapy. Eur Heart J 2011; 32: 900.
41. Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108(12): 1772-6.
42. Abdel-Wahab M, Mehilli J, Frerker C, et al. Comparison of balloon-expandable vs self-expandable valves in patients undergoing transcatheter aortic valve replacement. J Am Med Assoc 2014; 311: 1503-14
43. Edgar LW, Tay, Ronen Gurvitch, et al. Lichtenstein, Ronald Carere, Christopher Thompson, and John G. Webb. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. J Am Coll Cardiol Intv 2011; 4; 1290-7.
44. Vavuranakis M, Kalogeras K, Vrachatis D, et al. Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience. J Thromb Thromb 2015 Apr 12
45. Holmes DR, Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/ STS expert con-sensus document on transcatheter aortic valve replacement. J Am Coll Cardiol 2012; 59: 1200-54.
46. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on practice guidelines. J Thorac Cardiovasc Surg 2014; 148(1): e1-e132.
47. Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol 2012; 28: 520-8.
48. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of val-vular heart disease (version 2012). Eur Hear J 2012; 33: 2451-96
49. Lip GYH, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on. Eur Heart J 2014; 35(45): 3155-79.
50. Troels Højsgaard Jørgensen, Julie Bjerre Thygesen, Hans Gustav Hørsted Thyregod, et al. New-onset atrial fibrillation after surgical aortic valve replacement and transcatheter aortic valve implantation: a concise review. J Invasive Cardiol 2015; 27(1): 41-7
51. Gallego P, Roldan V, Marín F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-98.
52. Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18: 162-4.
53. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with at-rial fibrillation. Arch Intern Med 2010; 170: 1433-41.
54. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet ther-apy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2013; 127: 634-40.
55. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antipla-telet-warfarin therapy after coronary stenting. Eur Hear J 2007; 28: 726-32.
56. Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-74.
57. Bernard a, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost 2013; 110: 560-8.
58. Van Mieghem NM, Tchetche D, Chieffo A, et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol 2012; 110: 1361-7.
59. Kodali SK, Williams MR, Smith CR, et al. Two-year outcomes aftertranscatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-95
60. Halliday BP, Dworakowski R, Brickham B, Wendler O, MacCarthy P. Usefulness of periprocedural bleeding to predict outcome after trans-catheter aortic valve implantation. Am J Cardiol 2012; 109: 724-8.
61. Van Mieghem NM, Tchetche D, Chieffo A, et al. Incidence, predictors, and implications of access site complications with transfemoral transcatheter aortic valve implantation. Am J Cardiol 2012; 110: 1361-7.
62. Ussia GP, Barbanti M, Petronio AS, et al. Transcatheter aortic valveimplantation: 3-year outcomes of self-expanding CoreValve prosthesis. Eur Heart J 2012; 33: 969-76
63. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart 2013; 99: 860-5
64. Nuis RJ, Rodés-Cabau J, Sinning JM, et al. Blood transfusion and therisk of acute kidney injury after transcatheter aortic valve implantation. Circ Cardiovasc Interv 2012; 5: 680-8.
65. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aorticvalvereplacement for inoperable severe aortic stenosis. N Engl J Med 2012; 366: 1696-704
66. Thompson KA, Philip KJ, Schwarz ER. Clinical applications of bivalirudin in the cardiac catheterization laboratory. J Cardiovas Pharmacol Ther 2011; 16: 140-9.
67. Sergie Z, Lefèvre T, Van Belle E, et al. Current periprocedural anti-coagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombolysis 2013; 35: 483-93.
68. Moretti C, D’Amico M, D’Ascenzo F, et al. Impact on prognosis of periprocedural bleeding after TAVI: mid-term follow-up of a multicenter prospective study. J Interv Cardiol 2014; 27(3): 293-9.
69. Stepinska J, Czerwinska K, Witkowski A, et al. Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI). Cardiol J 2013; 20(2): 125-33.
70. Ngaage DL, Schaff HV, Barnes SA, et al. Prognostic implications of preoperative atrialfibrillation in patients undergoing aortic valve replacement: is there an argument for concomitant arrhythmia surgery? Ann Thorac Surg 2006; 82(4): 1392-9.
71. Kalavrouziotis D, Buth KJ, Vyas T, Ali IS. Preoperative atrial fibrillation decreases event-free survival following cardiac surgery. Eur J Cardiothorac Surg 2009; 36(2): 293-9.
72. Gaudino M, Andreotti F, Zamparelli R, et al. The -174G/C interleukin-6 polymorphism influ-ences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 2003; 108 (Suppl 1): II195-9.